Description
What is Cizumab (Bevacizumab) Injection?
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy.
Bevacizumab was approved for medical use in the United States in 2004. It is on the World Health Organization’s List of Essential Medicines It is listed for its use in treating eye disease.
Will this product be accessible across all regions of India?
Cizumab (Bevacizumab) can be made available in major Indian cities, including: Delhi, Gurgain, Noida, Chandigarh, Srinagar, Jammu, Hyderabad, Chennai, Bangalore, Ahmedabad, Surat, Mumbai, Pune, Kolkata, Jaipur, Jodhpur, Hyderabad, Lucknow, Patna.
To learn about the cost price of Bevacizumab or to order Bevacizumab online, please contact:
📞 Ms. Himanshi: 9999156233
📧 Email: sales@aarkpharma.co.in, sales@aarkpharma.com
We ensure genuine quality, secure delivery, and compliance with all buyer requirements.
Aark Pharma network in India (New Delhi | Lucknow | Varanasi | Chandigarh | Kolkata | Patna | Jodhpur)
Prior to consuming any medications, including Bevacizumab Injection it is advisable to seek guidance from a medical professional regarding its therapeutic advantages, usage instructions, and potential side effects.
List of available brand-name drugs in India for Bevacizumab Injection
Branded Generic Drugs for Bevacizumab Injection: Abevmy | Advamab | Avastin | Bevacirel | Bevarest | Bevatas | Bevicra | Bevnexxa | Krabeva | Syndyma | Versavo
NEWS / UPDATES
- Bevacizumab similar biologics launched in India.
- Enzene Biosciences launches Bevacizumab
- Dr. Reddy’s Launches VERSAVO (bevacizumab) in India
- Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India
- Biocon Biologics gets US FDA approval for Biosimilar Bevacizumab, expanding oncology portfolio





